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Objective To describe the first nosocomial outbreak of ampicillin-resistant Enterococcus faecium (ARE) in
Norway, where a few vancomycin-resistant strains have also been identified.
Methods All cases of ARE and vancomycin-resistant Enterococcus faecium (VRE) diagnosed by the medical
microbiological laboratories in a region inhabited by approximately 1 million people were registered. Isolates
obtained during the period 1 January 1995 to 31 December 1996 were characterized by pulsed field-gel
electrophoresis and the clinical data were recorded.
Results One hundred and forty-nine patients (64 males, 85 females, mean age 70.5 years) were infected with
ARE. Isolates from 115 cases were genomically related to the outbreak strain. Infections included bacteremia
(14), wound infections (31), urinary tract infections (97) and other infections (seven). Most had a severe
underlying disease and 93% of the patients had received antibiotics for a mean time of 23 days. Twenty-four
patients (16.1%) died during hospitalization. Four infections were caused by a vanB-type VRE that was
genomically related to the ARE outbreak strain. The prescription rate for vancomycin was low, but an increase
in vancomycin use paralleled the appearance of VRE. The highest monthly incidence rate was 2.5 per 1000
patient admissions in July 1996 declining to 0.5 in December 1996.
Conclusions The first nosocomial outbreak caused by ARE was observed in 1995 in Norway and is still
ongoing. One year after the onset, VRE occurred in wards which had a relatively high consumption of
vancomycin.
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INTRODUCTION
In recent years, enterococci have emerged as a significant cause
of nosocomial infections [1,2], accounting for about 8% of
hospital-acquired infections in the United States [3]. Urinary
tract infections are most common, but enterococci are also
frequently isolated from abdominal and surgical wound infec-
tions and are an important cause of bacteraemia and endocarditis
[4–7]. The majority of clinical enterococcal infections are Enter-
ococcus faecalis, but there is an increasing number of reports of
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infections caused by Enterococcus faecium [3]. The emergence of
enterococci as significant pathogens is a matter for concern
because these organisms are inherently resistant to a number of
antimicrobial agents, including cephalosporins and amino-
glycosides. Cell-wall-active drugs such as ampicillin and
vancomycin are only bacteriostatic. Enterococci have acquired
high-level resistance to aminoglycosides [8,9]. Later, ampicillin-
resistant enterococci [10,11] and eventually vancomycin-
resistant enterococci (VRE) emerged [12,13]. Multiple-drug
resistant enterococci (MDRE) combine inherent resistance of
Enterococcus spp. with resistance to ampicillin, high-level resist-
ance to aminoglycosides and glycopeptide resistance [3]. Such
strains seem to have a substantial potential for nosocomial
spread.
Both the selection of various resistant strains and the clonal
spread of ampicillin-resistant enterococci (ARE) have been
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reported [13,14]. Clonal outbreaks of infections caused by mul-
tiple-resistant E. faecium have been reported [15,16], and VRE
outbreaks have been described from several countries [17–21].
It is also evident that the genetic determinants for glycopeptide
resistance are transferable [16,22]. It is therefore important to
study both mechanisms for the spread of multiple-drug-resistant
enterococci and the spread of resistance factors independently.
The purpose of this study was to describe a nosocomial outbreak
of ampicillin-resistant E. faecium (ampicillin minimal inhibitory
concentration 32 mg/L) in which VRE emerged with clon-
ally related strains.
MATERIALS AND METHODS
Setting
Haukeland University Hospital is a fully specialized 1100-bed
hospital serving a population of 1 million as a referral hospital
and 300 000 as an emergency hospital. Deaconess Hospital
Haraldsplass is a 175 bed emergency hospital located nearby
serving the same population. Patients that have been hos-
pitalized in one of the hospitals will often be readmitted to the
other. The Department of Microbiology and Immunology at
Haukeland University Hospital serves these two hospitals and
also the three other emergency hospitals located in Hordaland
County. It is also the main service for outpatients in Hordaland
County (431 000 inhabitants). The number of bacteriological
specimen examined each year exceeds 80 000, some 50 000 of
which are from outpatients. There are also two collaborating
microbiological laboratories in the nearest two counties which
serve the rest of the hospitals and outpatients in the region.
With the exception of one clinical ARE and VRE case, these
two laboratories did not report any other ARE or VRE cases
during 1995 and 1996.
Patient inclusion
All patients with a clinical isolate of ARE detected between 1
January 1995 and 31 December 1996 at the Department for
Microbiology and Immunology were prospectively included.
One or more of the authors, who are specialists in infectious
diseases, recorded the clinical data of the patients. Unclear cases
were always discussed by at least two of the authors. The
data-set included diagnosis, length of hospital stay, antibiotics
prescribed, all wards visited, use of central venous catheters,
surgical procedures, use of urinary catheters and outcome. The
clinical diagnosis of infection was classified according to the
CDC definitions [23] and intra-hospital death registered as
attributable to enterococcal infection when active enterococcal
infection was clearly recognized as the major cause of the fatal
outcome [24]. Previous hospitalization with discharge within
the last month was added to the length of the actual hospital
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stay. Statistical patient data concerning the number of patients
admitted, average length of hospital stay and consumption of
antibiotics for each of the hospital units were recorded from
the annual hospital reports.
Identification of isolates
All isolates were identified by standard biochemical methods
[25]. At least one isolate of each pulsed field type (see below)
was verified as E. faecium by using a polymerase chain reaction
(PCR) method [26].
Antimicrobial susceptibility testing
The susceptibility of the isolates to different antimicrobial agents
(ampicillin, netilmicin, gentamicin, vancomycin and teico-
planin) was examined by an agar diffusion method [27] using
paper discs and PDM Antibiotic Sensitivity Medium (AB Bio-
disk, Solna, Sweden). Urine isolates were also tested against
ciprofloxacin, cotrimoxazole and nitrofurantoin using the same
method. The susceptibilities were categorized in three groups
(sensitive, intermediate, resistant) according to recom-
mendations given by The Norwegian Working Group on Anti-
biotics [28]. All isolates classified as resistant to aminoglycosides
were examined for high-level gentamicin resistance by a special
E-test (AB Biodisk). The minimal inhibitory concentrations
(MICs) of ampicillin, vancomycin and teicoplanin were deter-
mined for the majority of ARE isolates during the outbreak by
E-test (AB Biodisk).
Pulsed-field gel electrophoresis
One hundred and forty-two isolates were available for pulsed-
field gel electrophoresis (PFGE) as performed on Sma1 (Pro-
mega Corp, Madison, WI, USA) digested genomic DNA as
previously described [29] using the Rothapor type V elec-
trophoresis unit (Biometra GmbH, Germany). DNA digests
were loaded on 1% agarose gels with 2–15 s pulses at 180 V
and 22°C for 20 h. The resulting patterns were interpreted as
described [30].
Detection of van-genes
All isolates with vancomycin MIC  2 mg/L were analysed for
the presence of vanA, vanB and vanC resistance genes by PCR.
Preparation of DNA and PCR amplification was performed as
described elsewhere [31]. The primers used for detection of the
vanB1 gene were those described by Clark et al. [32]. For vanB2
the following primers were used: Forward: 5? CAA AGC TCC
GCA GCT TGC ATG 3? (nucleotide positions 5340–5360).
Reverse: 5? TGC ATC CAA GCA CCC GAT ATA C 3?
(nucleotide position 5823–5802).
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Statistical data
Numbers of patients admitted and numbers of days in hospital
for different units of Haukeland University Hospital were col-
lected from the official administrative database used in the
hospital. The data for consumption of antimicrobial agents were
provided from the database of the hospital pharmacy as net
delivered amount of individual drugs counted as defined daily
dosages (DDD).
Statistical methods
Statistical analyses were performed by the Statistical Program
for Social Sciences (SPSS-PC + version 7.0 SPSS inc., Chicago,
IL). The Pearson correlation coefficient was calculated for cor-
relation between the ARE incidence and antibiotic con-
sumption and P-values were calculated for two-tailed
distribution.
RESULTS
Clinical findings
A total of 149 patients (64 males and 85 females, mean age 70.5
years) had an ARE isolated from a clinical specimen. The basic
characteristics for these patients are shown in Table 1. One
hundred and twenty-three patients were hospitalized at Hau-
keland University Hospital, seven were outpatients there, 17
patients were hospitalized at Deaconess Hospital Haraldsplass
and two patients had not visited these hospitals at all. The mean
hospital stay was 43.2 days, compared with 6.5 days for all
patients in the two hospitals. One hundred and four patients
had the infection detected during hospitalization, 19 within 1
month after discharge, and 17 within 6 months of hospital-
ization. Seven patients had visited the outpatient clinic only
during the last 6 months. Of the two patients who had not
Table 1 Demographic characteristics and underlying diseases
for 149 patients infected with ampicillin-resistant Enterococcus
faecium
No. of patients included 149
Female, no. (%) 85 (57)
Age, mean (range) 70.5 (1–95)
No. of patients with different
underlying diseases (%) n = 143
malignant 43 (30.0)
infection 30 (21.0)
cardiovascular 24 (16.8)
gastrointestinal 16 (11.2)
urogenital 9 (6.3)
immunological 6 (4.2)
bone and joint 5 (3.5)
other diseases 10 (7.0)
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visited either of the two hospitals, one had been hospitalized at
another hospital, which had previously had a patient with ARE
transferred from our hospital. The other patient without hos-
pital contact was a nursing home patient with an E. faecium
unrelated to the outbreak strain. The dominating ARE infec-
tion type was urinary tract infection, but more severe infections
occurred (Table 2). Long hospital stay was a reflection of the
severe underlying disease. Malignancy was the most frequent
underlying disease, followed by infections and cardiovascular
disease (Table 1). The case fatality rate during the hospital
stay was 16.1% and 4.7% was attributable to ARE as active
enterococcal infection was clearly recognized as the major cause
of the fatal outcome.
Data on antibiotic consumption was available for the 140
ARE patients admitted to the two hospitals (94% of all the
patients) (Table 2). The rest were omitted because of incom-
plete data (seven outpatients and two admitted to another hos-
pital). Of these 140 patients, 121 (86%) had received
antimicrobial agents within the last month prior to the entero-
coccal infection. This figure also includes drugs prescribed
before hospitalization. The mean duration of treatment for
patients receiving antibiotics was 22.3 days. The most fre-
quently used agents were cephalosporins, followed by peni-
cillins, aminoglycosides and quinolones. Glycopeptides were
Table 2 Patient characteristics for 149 patients with clinical
infection caused by ampicillin-resistant Enterococcus
faecium (ARE)
Distribution of infections, no. (%)
urinary tract infection 97 (65.1)
wound or surgical site 31 (20.8)
bacteraemia 14 (9.4)
other 7 (4.7)
No. of hospital days, mean (range) 43.2 (1–285)
Antibiotics prior to MRE infection
(data available for 140 patients)
No. of patients receiving antibiotics (%) 121 (86.4)
Days on antibiotics, mean (range) 22.3 (1–134)
No. of antibiotics prescribed, mean (range) 2.7 (1–8)
No. of patients receiving specific
antimicrobial agents (n = 121)
penicillins 66 (50.0)
cephalosporins 81 (66.9)
fluoroquinolones 38 (31.4)
metronidazole 28 (23.1)
glycopeptides 10 (8.3)
trimethoprim-sulfamethoxazole 13 (10.7)
trimethoprim 4 (3.3)
clindamycin 13 (10.7)
aminoglycosides 40 (33.1)
carbapenems 21 (17.4)
Mortality, crude – no. of deaths (%) 24 (16.1)
Mortality, attributable – no. of deaths (%)* 7 (4.7)
*Active ARE-infection clearly recognized as the major cause of death.
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given to 8.3% of the patients receiving antimicrobial agents.
None of the patients with vancomycin-resistant enterococci
had received glycopeptide antibiotics, but they were admitted
to wards with a high general consumption of vancomycin
(Figure 1).
Case distribution
The epidemic started at the Haukeland University Hospital and
spread to the nearby Deaconess Hospital Haraldsplass with a
delay of about 6 months. The first case with ARE was detected
in January 1995. Isolates from the first two patients were not
genomically related to the outbreak strain. In 1994 two cases
with infections due to E. faecium having reduced susceptibility
to ampicillin (MIC: 8–16 mg/L) were observed, but no cases
with ampicillin-resistant strains. The first few patients had been
hospitalized in either the central intensive care unit, in a surgical
ward or one of the medical wards that later had several ARE
patients or they had been moved between these wards The
epidemic curve for the ARE cases are shown in Figure 2. All
the VRE cases appeared at the peak of the epidemic, between
March and July 1996. Clinical and epidemiological charac-
teristics for these patients are shown in Table 3.
The infection control program for the hospital was reinforced
Figure 1 Mean incidence of infections caused by ampicillin-resistant Enterococcus faecium and prescription of antibiotics in selected depart-
ments during 1995 and 1996. Seventy-six per cent of the ARE-cases within the medical department were in three wards noted as high
prevalence wards. The other three medical wards were noted as low prevalence wards.
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by elements from the recommendations given for VRE [33].
Special efforts were made to strengthen the general barrier
precautions for patients admitted to the two wards with highest
prevalence of ARE infection. All staff members were reminded
about hand-washing, use of uniform and gloves and gowns
when indicated. The wards were supervised intensively by
infection-control nurses. All patients with VRE infection and
patients with uncontrolled ARE infection were moved to iso-
lation facilities. Several classes were held to educate the staff
about the epidemic and the urgent need for their compliance.
Updated guidelines for prescription of antimicrobial agents
were distributed to all the physicians. The routines in the micro-
biologic laboratories were reinforced so that all cases of ARE
and VRE were reported immediately to the wards and also
registered by the infection-control team. These efforts were
initiated during March and April 1996.
Within Haukeland University Hospital and its outpatient
clinics, 70 cases were detected at the medical department, 24 at
the surgical department, eight at the intensive care unit, eight at
the orthopaedic department, five at the department for cardiac
diseases and four or less at other departments. Within the medi-
cal department, three wards (out of six) had 53 of the 70 cases
(76%). The paediatric department had one case at the outpatient
clinic, the department for gynaecology one case, and the
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Figure 2 Distribution of patients infected by ampicillin-resistant Enterococcus faecium at the Haukeland University Hospital during 1995 and
1996.
 outbreak-strain (PFGE-1); related cluster (PFGE-7); other related strains (11 different patterns); unrelated cluster (PFGE-8);  other
unrelated strains (11 different patterns).
oncology department had three cases. No case was found at the
burns unit. The incidence of ARE disease was highest in the
ICU with 1751 cases per 106 patient days, followed by the
medical department with 828 cases and surgical department
with 355 cases per 106 patient days (Figure 1). Fourteen of the
17 cases at Deaconess Hospital Haraldsplass were located in the
medical department and three in the surgical department.
Microbiological characterization
One hundred and forty-five of the 149 patients (97%) were
infected with E. faecium which were sensitive to glycopeptides,
but resistant to all other antibiotics tested. The typical MIC
of ampicillin was 64 mg/L, gentamicin 6 mg/L, vancomycin
1.5 mg/L, and teicoplanin 0.125 mg/L. Four of the isolates
showed reduced susceptibility or resistance to vancomycin
(MIC range 8–12 mg/L). The vanB gene was detected in all
these isolates. All isolates were sensitive to teicoplanin. High-
level gentamicin resistance was not detected and the outbreak
strain showed a MIC of gentamicin of 6 mg/L. One hundred
and forty-two isolates from 131 of the 149 patients were avail-
able for PFGE analysis (Table 4). Altogether 27 different PFGE
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patterns were detected, 14 related and 12 unrelated, whereof
two patterns were found only in follow-up isolates. Repetitive
isolates were available from 11 patients. In nine of these patients,
only one pattern was detected. The distribution of PFGE pat-
terns from primary isolates in different units is shown in Table 5.
As isolates from 77 patients showed identical patterns of Sma1-
digested DNA on PFGE, this was defined as the outbreak strain.
Isolates from 38 patients had two to six band differences, and
these were defined as being related to the outbreak strain
according to the definitions of Tenover et al. [30]. Isolates from
16 patients showed more than seven bands different from the
outbreak strain, and thus differed from the outbreak strain. Two
of the four vancomycin-resistant isolates were indistinguishable
from the outbreak strain, and the two others were closely
related, with only two bands of difference.
Comparison of antibiotic consumption and ARE incidence at depart-
ment and ward level
Since there were marked differences in incidence of ARE
between departments (Figure 1) which we could not explain
by the severity of disease, mean duration of hospital stay, rou-
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Table 4 Distribution of 131 ampicillin-resistant Enterococcus
faecium isolates according to differences in pulsed field gel
electrophoresis (PFGE) patterns
PFGE pattern Genomic relation* No. of patients
1 Outbreak strain 77
2 Related 2
6 Related 2
7 Related 13
14 Related 3
17 Related 2
18 Related 5
19 Related 6
20 Related 1
21 Related 1
23 Related 1
25 Related 1
26 Related 1
4 Unrelated 1
5 Unrelated 1
8 Unrelated 5
9 Unrelated 1
10 Unrelated 1
11 Unrelated 1
12 Unrelated 1
13 Unrelated 1
15 Unrelated 1
16 Unrelated 1
22 Unrelated 1
27 Unrelated 1
*The genomic relatedness is defined as identical, related and unre-
lated to the outbreak strain according to Tenover et al. [30].
Table 5 Distribution of patients infected with ampicillin-resistant Enterococcus faecium: genomically identical, related and
unrelated pulsed field gel electrophoresis (PFGE) patterns
PFGE-pattern
Medical service (department) Identical Related Not related Not available for PFGE All
Haukeland Hospital
Internal medicine 41 15 8 6 70
Surgery 10 6 4 4 24
Intensive care unit 5 1 2 8
Orthopaedic 3 4 1 8
Cardiology 4 1 5
Dermatology 3 1 4
Neurology 2 2
Oncology 2 2
Other units* 2 3 2 7
Haraldsplass Hospital 7 7 3 17
Other hospital or not hospitalized 1 1 2
Totals 77 38 16 18 149
*None of these units had more than one patient with ARE-infection.
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tines to prevent spread of ARE, variation of antibiotic con-
sumption was examined. There appeared to be a covariation
between ARE incidence and total antibiotic consumption at
department level with a Pearson correlation coefficient (R)
of 0.83 (95% confidence interval 0.61–0.93 and P  0.0001).
There was no correlation between ampicillin consumption and
incidence of ARE. The consumption of vancomycin was high
at the intensive care unit (613 DDD per 104 hospital days) and
the wards in the medical department with high ARE incidence
(516–1232 DDD per 104 hospital days) compared with all other
wards (31 DDD per 104 hospital days). The three medical wards
with highest ARE incidence had also an increase in vancomycin
consumption from 390 DDD in 1993 to 891 DDD in 1996,
compared with 738 DDD (1993) and 821 DDD (1996) for all
other wards at the hospital. Three out of the four VRE cases
were in two of these three wards.
DISCUSSION
In Scandinavia there have been few reports of multiple-drug
resistant enterococci, but an increasing rate of ampicillin resist-
ance has been reported [34]. The first VRE case was observed
in June 1995 [35], and minor outbreaks have been described in
Denmark [18] and Sweden [31]. Only one clinical VRE case
has previously been reported in Norway [36]. However, VRE
carriers have been found among poultry workers. These strains
have been vanA type and susceptible to ampicillin [37].
In our hospital E. faecalis has until recently been the dom-
inating enterococcal species in blood cultures and virtually all
enterococcal isolates have been fully susceptible to ampicillin
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[38]. The reason why multiple-drug-resistant enterococci and
especially VRE, are uncommon in Scandinavia and their
appearance has been delayed compared with other European
countries may be the restrictive use of antibiotics [39].
The different modes by which antibiotic resistant enterococci
are spread may not be discovered in an outbreak situation due
to lack of knowledge of the epidemiological background [40].
Previous reports on nosocomial infections caused by multiple-
drug-resistant enterococci have demonstrated both a selection
and a spread of different antibiotic-resistant strains and the
clonal spread of certain epidemic strains [19]. As gentamicin
and glycopeptide resistance have emerged, reports have shown
that both clonal [14,41] and nonclonal [2,42] spread occur. It
is evident that some strains have a greater potential for spread
than others. As the genes regulating antimicrobial resistance,
especially glycopeptide resistance, can be independently trans-
ferred [16], the epidemiological pattern may be complex. The
ARE described in the present paper belong mainly to the
same clonal complex judged by PFGE indicating exogenous
acquisition of ARE. The strain most probably has acquired
resistance genes from the environment, thus becoming van-
comycin resistant.
Our patients had been hospitalized for a long time prior to
ARE-infection, had high consumption of antibiotics and a high
proportion of the patients had severe underlying diseases. These
findings are in accordance with those in other outbreaks
[5,14,43]. Many cases of multiple-drug-resistant enterococcal
infections have been described in debilitated patients with pro-
longed hospital stay [19,44,45] who have received multidrug
regimens or antimicrobial agents for a long time [15,43–46].
Use of imipenem and metronidazole have been reported to
facilitate ARE [24] and the use of vancomycin [20,41,44,46,47],
third generation cephalosporins [43,45], or agents with activity
against anaerobic bacteria [17], have been shown to facilitate
VRE colonization or infection. Failure in hospital infection
control practices has also been claimed to cause the spread of
VRE in hospital environments [48].
Several factors have also been suggested as modifiers of the
outcome of enterococcal infection, among them ampicillin
resistance [5,24]. None of the fatal cases in this study was found
in patients without underlying severe and life-threatening
diseases. However, larger case-control studies are needed to
address such questions.
Patients with ARE-infections had been admitted to many
wards at Haukeland University Hospital during the observation
period and many of them had also moved between wards and
departments (data not shown) and so patients in nearly every
department could have been exposed. However, the majority
of ARE patients at this hospital was found in three medical
wards. We therefore compared some characteristics of the dif-
ferent units. A strong correlation was found between the inci-
dence of ARE-infection and antibiotic consumption. There
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 19–28
was no correlation between the consumption of ampicillin and
the incidence of ampicillin resistance. Others have reported
such correlation [14]. Within the Department of Internal Medi-
cine, there were no significant differences between the mean
length of hospital stay or mean age for the patients at the high
prevalence wards and other wards. As far as we were able to
recognize, there were no great differences in carrying out the
infection control program. However, when we strengthened
the efforts to adhere to the program, we observed a significant
reduction in the overall incidence of ARE, which was most
clearly demonstrated in the high prevalence wards.
Even though the total consumption of vancomycin was low
in our hospital, three of the VRE cases appeared in wards with
a relatively high consumption. The fourth VRE-patient was
hospitalized in a dialysis unit where a relatively high proportion
of the patients receive low doses of vancomycin. The vanco-
mycin exposure in this ward may therefore be higher than
reflected by the total vancomycin consumption. None of the
VRE-patients had received glycopeptides prior to the infection.
As these isolates were clonally identical or nearly identical and
appeared during a period of less than 3 months, it is likely that
the patients have been cross-infected by a VRE-variant of the
outbreak strain, and that this strain had acquired the vanB gene.
However, VRE have not been found by faecal surveillance
(data not shown). Since this variant disappeared, it probably
had less potential for spread than the outbreak strain.
Half the vancomycin consumption of the hospital was within
the three wards in the medical department with the highest
incidence of ARE. The whole increase in vancomycin con-
sumption at the hospital during the period 1993–96 was attribu-
table to these wards. It seems that vancomycin consumption at
the ward level, was an important reason for the emergence of
VRE
In conclusion, the consumption of antibiotics appears to be
an indicator for high incidence of ARE. The outbreak strain
developed vancomycin resistance in those wards with the high-
est vancomycin consumption.
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